[{"uuid": "8a5ca08f-6791-3a69-aaa0-1062d9de68e4", "title": "Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-adpt-soars-18-133300359.html", "providerPublishTime": 1737034380, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/GOd9_vmyYsGT_kCyxDvLhA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1570355885f35f6c0be0cbca2e936d8e", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/995uX4ZXeYoRvv1Vrzqnzw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1570355885f35f6c0be0cbca2e936d8e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT", "ACLX"]}, {"uuid": "6653efb9-742b-38a4-93c6-09833694f379", "title": "Arcellx Insider Sold Shares Worth $1,355,024, According to a Recent SEC Filing", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/arcellx-insider-sold-shares-worth-082201517.html", "providerPublishTime": 1736756521, "type": "STORY", "relatedTickers": ["ACLX"]}, {"uuid": "0c76eb68-d211-361c-9926-d2b180417f25", "title": "Can Analysts Pick Stocks? I Doubt It", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/analysts-pick-stocks-doubt-162204972.html", "providerPublishTime": 1736785324, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Y4gluffW4ohl4mzd9tnd5g--~B/aD0zNjY7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/772740eaffb8e863e2e0ea40286fc545", "width": 550, "height": 366, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/TjL8be4Vd0Z_jlMg7C.CkA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/772740eaffb8e863e2e0ea40286fc545", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["SLB"]}, {"uuid": "92c82565-1a5f-3d97-ac5a-d1af63f4eb91", "title": "Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/arcellx-insider-sold-shares-worth-082252718.html", "providerPublishTime": 1736756572, "type": "STORY", "relatedTickers": ["ACLX"]}, {"uuid": "37268ea4-c277-3fe9-909a-1f9f26563d86", "title": "Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/guardant-health-gh-soars-6-091400294.html", "providerPublishTime": 1736241240, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LTsYiBKfddfbKBa6A3ycbg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/db2169c6d655802146ef1d23651e1726", "width": 900, "height": 602, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fyo4zOtIjF_u_bjG6H_dyQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/db2169c6d655802146ef1d23651e1726", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GH", "ACLX"]}, {"uuid": "470b8c46-747c-3d2c-b556-ec8e28de10bb", "title": "Arcellx Insider Sold Shares Worth $2,244,896, According to a Recent SEC Filing", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/arcellx-insider-sold-shares-worth-081617263.html", "providerPublishTime": 1736237777, "type": "STORY", "relatedTickers": ["ACLX"]}, {"uuid": "bce16345-a41a-3230-b631-28e9996ebdc4", "title": "Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/arcellx-aclx-stock-jumps-6-112700551.html", "providerPublishTime": 1730978820, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/iI5piNm2vFo3HCLgtvsz_w--~B/aD02MDM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9bb0f7469abe2b88d816d427f27fa1ed", "width": 1000, "height": 603, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6NNLdPT14oERda7Yewytsw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9bb0f7469abe2b88d816d427f27fa1ed", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX", "LQDA"]}, {"uuid": "f1bf2fd3-3370-3f53-8fc3-a97b87be5d69", "title": "Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/arcellx-inc-aclx-reports-q3-221509219.html", "providerPublishTime": 1731017709, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/wbCMwMtKIoXj_iQA0ego4g--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295", "width": 900, "height": 506, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Gkx1uVeFgGgcGf5Jyi6uoA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX"]}, {"uuid": "653d9aff-3590-3c3a-9e65-daa70f0a0b4e", "title": "5 Biotech Breakthrough Stocks to Watch in 2025", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/5-biotech-breakthrough-stocks-watch-143900028.html", "providerPublishTime": 1734964740, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/H5j0X5VJ3peIo6cA0ud3Qg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["OCGN", "INSM", "BEAM"]}, {"uuid": "1d536aba-9e9b-3821-89c9-1c8b30d6aeb8", "title": "Arcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/arcellx-says-trial-multiple-myeloma-091733391.html", "providerPublishTime": 1733735853, "type": "STORY", "relatedTickers": ["ACLX"]}, {"uuid": "2bb092cb-0134-3e38-b3b1-f033e5c9f3ed", "title": "UBS Raises Price Target on Arcellx to $114 From $106, Maintains Buy Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/ubs-raises-price-target-arcellx-122635902.html", "providerPublishTime": 1733833595, "type": "STORY", "relatedTickers": ["ACLX"]}, {"uuid": "865c7c23-4526-3e20-8475-544661d13a6a", "title": "Arcellx Stock Earns 82 Relative Strength Rating", "publisher": "Investor's Business Daily", "link": "https://finance.yahoo.com/m/865c7c23-4526-3e20-8475-544661d13a6a/arcellx-stock-earns-82.html", "providerPublishTime": 1735326540, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/yK.1mixnMFPJb1QlWEF63Q--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/4f55f705c42c63544ad6253ec4f7e290", "width": 1000, "height": 563, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/VVNQlheY54ITcHMqygWRXA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/4f55f705c42c63544ad6253ec4f7e290", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADMA", "ACLX", "CPRX"]}, {"uuid": "989af7fa-8e1e-37fe-8a39-89a7f4ca4791", "title": "Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/gilead-sciences-arcellx-apos-car-193104515.html", "providerPublishTime": 1733859064, "type": "STORY", "relatedTickers": ["GILD", "ACLX"]}, {"uuid": "2088bdfa-d67a-352b-9f3f-8144ffcb563b", "title": "Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/arcellx-aclx-outperforming-other-medical-144011848.html", "providerPublishTime": 1731076811, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619", "width": 900, "height": 506, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/twDpSkUZEyzUBc0qEMHAqw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX", "ABBV"]}, {"uuid": "29ad9b91-c6df-386a-adf3-fa80a7343b83", "title": "Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/arcellxs-cancer-cell-therapy-shows-125013309.html", "providerPublishTime": 1733748613, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/lrLqzErYtt67G6m_brZx1A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/2ed13b35f5b8c4f41b3dac9c81d60df9", "width": 1000, "height": 563, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/jIb3UwIojK9XzNDVBYeNww--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/2ed13b35f5b8c4f41b3dac9c81d60df9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX"]}, {"uuid": "79f8bad2-f65c-379c-8fa1-facea6c57c98", "title": "Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/arcellx-announces-positive-data-immagine-040000047.html", "providerPublishTime": 1733716800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/CFG8z5HWByP2us2nm79JHQ--~B/aD0xMjMzO3c9NDI0NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/c5bfb71bc06674ba766ed33926515f70", "width": 4244, "height": 1233, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ITF_.NxD.JH_ntztbOLJGg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c5bfb71bc06674ba766ed33926515f70", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX"]}, {"uuid": "9a5837ee-c048-3dc7-9090-cc076aa38653", "title": "Arcellx Third Quarter 2024 Earnings: Misses Expectations", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/arcellx-third-quarter-2024-earnings-145534703.html", "providerPublishTime": 1731164134, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 945, "height": 636, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NamfX5LEtyScIu4YmRG2hg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX"]}, {"uuid": "511673bf-3035-3087-807e-b06fbee6e522", "title": "Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/looking-top-momentum-pick-why-170011085.html", "providerPublishTime": 1731517211, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248", "width": 900, "height": 467, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/K_VbSLl5PAgBcdM4TzmL5A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX"]}, {"uuid": "5c76a7a7-e962-3dad-91c0-4aeb38c49867", "title": "Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/arcellx-provides-third-quarter-2024-210000121.html", "providerPublishTime": 1731013200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/0l84ETnjPKqf0BEmALYd5w--~B/aD0xMjMzO3c9NDI0NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/7ebcdd2e484dd54d7e41df3e03850280", "width": 4244, "height": 1233, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/wb1kK_OgDavI8qHJ9DuP.Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7ebcdd2e484dd54d7e41df3e03850280", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX"]}, {"uuid": "700d310d-526d-3823-b2d8-7f585034e438", "title": "Arcellx price target raised to $106 from $81 at Morgan Stanley", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/arcellx-price-target-raised-106-114100738.html", "providerPublishTime": 1730979660, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/JR57pJ12h3k1wjWsvT64Rw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACLX"]}]